• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by JATT II Acquisition Corp

    4/24/26 4:21:31 PM ET
    $JATT
    Get the next $JATT alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    JATT II Acquisition Corp.

    (Name of Issuer)


    Ordinary shares, par value $0.0001 per share

    (Title of Class of Securities)




    G50765109

    (CUSIP Number)
    04/17/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    G50765109


    1Names of Reporting Persons

    Great Point Partners, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    500,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    500,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    500,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.41 %
    12Type of Reporting Person (See Instructions)

    IA, OO


    SCHEDULE 13G

    CUSIP Number(s):
    G50765109


    1Names of Reporting Persons

    Dr. Jeffrey R. Jay, M.D.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    500,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    500,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    500,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.41 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    CUSIP Number(s):
    G50765109


    1Names of Reporting Persons

    Ms. Lillian Nordahl
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    500,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    500,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    500,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.41 %
    12Type of Reporting Person (See Instructions)

    HC, IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    JATT II Acquisition Corp.
    (b)Address of issuer's principal executive offices:

    153 Central Avenue, C/O 56, Westfield, NJ 07091
    Item 2. 
    (a)Name of person filing:

    Great Point Partners, LLC Dr. Jeffrey R. Jay, M.D. Ms. Lillian Nordahl The Reporting Persons have entered into a Joint Filing Agreement, dated April 24, 2026, a copy of which is filed with this SCHEDULE 13G as Exhibit A, pursuant to which the Reporting Persons have agreed to file this statement jointly in accordance with the provisions of Rule 13d-1(k)(1) under the Act.
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of each of the Reporting Persons is 165 Mason Street, 3rd Floor Greenwich, CT 06830
    (c)Citizenship:

    Great Point Partners, LLC is a limited liability company organized under the laws of the State of Delaware. Dr. Jeffrey R. Jay, M.D. is a citizen of the United States. Ms. Lillian Nordahl is a citizen of the United States.
    (d)Title of class of securities:

    Ordinary shares, par value $0.0001 per share
    (e)CUSIP Number(s):

    G50765109
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    500,000
    (b)Percent of class:

    6.41%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    500,000

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    500,000 The information required by Items 4(a) - (c) is set forth in Rows (5) - (11) of the cover pages for the Reporting Persons and is incorporated herein by reference. The percentage set forth in Row (11) of the cover pages for the Reporting Persons are based on a total of 7,800,000 shares outstanding, as reported by the Issuer in its Form 424B Prospectus filed with the Securities and Exchange Commission (the "SEC") on April 17, 2026. Biomedical Value Fund, L.P. ("BVF") is the record holder of 330,000 shares (the "BVF Shares"). Great Point Partners, LLC ("Great Point") is the investment manager of BVF, and by virtue of such status may be deemed to be the beneficial owner of the BVF Shares. Each of Dr. Jeffrey R. Jay, M.D. ("Dr. Jay"), as Senior Managing Member of Great Point, and Ms. Lillian Nordahl ("Ms. Nordahl"), as Managing Director of Great Point, has voting and investment power with respect to the BVF Shares, and therefore may be deemed to be the beneficial owner of the BVF Shares. Biomedical Offshore Value Fund, Ltd. ("BOVF") is the record holder of 170,000 shares (the "BOVF Shares"). Great Point is the investment manager of BOVF, and by virtue of such status may be deemed to be the beneficial owner of the BOVF Shares. Each of Dr. Jeffrey R. Jay, M.D. ("Dr. Jay"), as Senior Managing Member of Great Point, and Ms. Lillian Nordahl ("Ms. Nordahl"), as Managing Director of Great Point, has voting and investment power with respect to the BOVF Shares, and therefore may be deemed to be the beneficial owner of the BOVF Shares. Notwithstanding the above, Great Point, Dr. Jay and Ms. Nordahl disclaim beneficial ownership of the BVF Shares and the BOVF Shares, except to the extent of their respective pecuniary interests.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    See Item 4.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Great Point Partners, LLC
     
    Signature:/s/ Dr. Jeffrey R. Jay, M.D
    Name/Title:Dr. Jeffrey R. Jay, M.D - Senior Managing Member
    Date:04/24/2026
     
    Dr. Jeffrey R. Jay, M.D.
     
    Signature:/s/ Dr. Jeffrey R. Jay, M.D
    Name/Title:Dr. Jeffrey R. Jay, M.D
    Date:04/24/2026
     
    Ms. Lillian Nordahl
     
    Signature:/s/ Ms. Lillian Nordahl
    Name/Title:Ms. Lillian Nordahl
    Date:04/24/2026
    Exhibit Information

    JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned hereby agree as follows: (i) Each of them is individually eligible to use the SCHEDULE 13G to which this Exhibit is attached, and such SCHEDULE 13G is filed on behalf of each of them; and (ii) Each of them is responsible for the timely filing of such SCHEDULE 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate. Dated: April 24, 2026 Great Point Partners, LLC By: /s/ Dr. Jeffrey R. Jay, M.D. Dr. Jeffrey R. Jay, M.D., as Senior Managing Member Dr. Jeffrey R. Jay, M.D. By: /s/ Dr. Jeffrey R. Jay, M.D. Dr. Jeffrey R. Jay, M.D. Ms. Lillian Nordahl By: /s/ Ms. Lillian Nordahl Ms. Lillian Nordahl

    Get the next $JATT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JATT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $JATT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Lisicki Robert

    4 - Zura Bio Ltd (0001855644) (Issuer)

    1/26/24 11:33:20 AM ET
    $JATT

    SEC Form 4 filed by Ploos Van Amstel Arnout

    4 - Zura Bio Ltd (0001855644) (Issuer)

    1/26/24 11:32:02 AM ET
    $JATT

    SEC Form 4 filed by Thiara Parvinder

    4 - Zura Bio Ltd (0001855644) (Issuer)

    1/26/24 11:30:45 AM ET
    $JATT

    $JATT
    SEC Filings

    View All

    JATT II Acquisition Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - JATT II Acquisition Corp. (0002112446) (Filer)

    4/24/26 5:10:18 PM ET
    $JATT

    SEC Form SCHEDULE 13G filed by JATT II Acquisition Corp

    SCHEDULE 13G - JATT II Acquisition Corp. (0002112446) (Subject)

    4/24/26 4:48:44 PM ET
    $JATT

    SEC Form SCHEDULE 13G filed by JATT II Acquisition Corp

    SCHEDULE 13G - JATT II Acquisition Corp. (0002112446) (Subject)

    4/24/26 4:21:31 PM ET
    $JATT

    $JATT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    JATT II Acquisition Corp Announces Closing of $60,000,000 Initial Public Offering

    WESTFIELD, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- JATT II Acquisition Corp (the "Company") announced the closing of its initial public offering of 6,000,000 ordinary shares at an offering price of $10.00 per ordinary share on April 20, 2026. Total gross proceeds from the offering were $60,000,000 before deducting underwriting discounts and commissions and other offering expenses payable by the Company. The ordinary shares began trading on the Nasdaq Global Market ("NASDAQ") under the ticker symbol "JATT" on April 17, 2026. Guggenheim Securities, LLC is acting as sole book-running manager. The Company has granted the underwriters a 45-day option to purchase up to 900,000 additional ordi

    4/20/26 4:30:00 PM ET
    $JATT

    JATT II Acquisition Corp Announces Pricing of $60,000,000 Initial Public Offering

    WESTFIELD, N.J., April 16, 2026 (GLOBE NEWSWIRE) -- JATT II Acquisition Corp (the "Company"), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company, today announced the pricing of its initial public offering of 6,000,000 ordinary shares at an offering price of $10.00 per ordinary share. The ordinary shares are expected to trade on the Nasdaq Global Market ("NASDAQ") under the ticker symbol "JATT" beginning April 17, 2026. The offering is expected to close on April 20, 2026, subject to customary closing conditions. Guggenheim Securities, LLC is acting as sole book-running manager. The Company has granted the underwriters a 45-day option to purcha

    4/16/26 6:30:00 PM ET
    $JATT

    Zura Bio Limited Announces Closing of Business Combination with JATT Acquisition Corp

    Zura Bio Limited to trade on Nasdaq as a clinical-stage biotechnology company focused on immunology Business combination results in approximately $65 million in gross cash proceeds to support research and development initiatives and potential future acquisitions Combined company to trade on Nasdaq under ticker "ZURA" commencing March 21, 2023 Zura Bio Limited ("Zura"), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced the closing of its business combination with JATT Acquisition Corp, a special purpose acquisition company (NYSE:JATT) ("JATT"), on March 20, 2023. The business combination was

    3/21/23 6:13:00 AM ET
    $JATT

    $JATT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by JATT Acquisition Corp (Amendment)

    SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

    2/14/24 4:39:38 PM ET
    $JATT

    SEC Form SC 13G/A filed by JATT Acquisition Corp (Amendment)

    SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

    2/14/24 9:02:53 AM ET
    $JATT

    SEC Form SC 13G/A filed by JATT Acquisition Corp (Amendment)

    SC 13G/A - Zura Bio Ltd (0001855644) (Subject)

    2/14/24 6:05:55 AM ET
    $JATT